Monte Rosa Therapeutics, Inc. (GLUE)
NASDAQ: GLUE · Real-Time Price · USD
4.365
-0.075 (-1.69%)
Aug 14, 2025, 2:18 PM - Market open
Monte Rosa Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 |
| Cash & Equivalents | 69.43 | 224.25 | 128.1 | 54.91 | 346.07 | 41.7 | Upgrade
|
| Short-Term Investments | 221.17 | 147.9 | 104.31 | 207.91 | - | - | Upgrade
|
| Cash & Short-Term Investments | 290.59 | 372.15 | 232.41 | 262.83 | 346.07 | 41.7 | Upgrade
|
| Cash Growth | 10.83% | 60.12% | -11.57% | -24.05% | 729.93% | 595.56% | Upgrade
|
| Other Receivables | 2.37 | 0.17 | 0.51 | 7.66 | - | 0.1 | Upgrade
|
| Receivables | 2.37 | 0.17 | 0.51 | 7.66 | - | 0.1 | Upgrade
|
| Prepaid Expenses | 6.5 | 5.12 | 3.29 | 4.44 | 2.6 | 1.79 | Upgrade
|
| Restricted Cash | - | - | - | 0.96 | - | - | Upgrade
|
| Total Current Assets | 299.47 | 377.44 | 236.21 | 275.89 | 348.67 | 43.59 | Upgrade
|
| Property, Plant & Equipment | 54.73 | 56.31 | 62.61 | 61.91 | 12.33 | 4.62 | Upgrade
|
| Other Long-Term Assets | 5.4 | 4.98 | 4.93 | 4.6 | 5.34 | 1.16 | Upgrade
|
| Total Assets | 359.59 | 438.73 | 303.76 | 342.39 | 366.33 | 49.38 | Upgrade
|
| Accounts Payable | 5.58 | 17.22 | 11.15 | 7.86 | 6.56 | 7.07 | Upgrade
|
| Accrued Expenses | 12.26 | 15.43 | 12.93 | 9.56 | 9.24 | 1.13 | Upgrade
|
| Current Portion of Leases | 4.09 | 3.71 | 3.16 | 3.13 | - | - | Upgrade
|
| Current Unearned Revenue | 18.41 | 117.23 | 17.68 | - | - | - | Upgrade
|
| Other Current Liabilities | 1.51 | 3.35 | 1.67 | 5.02 | 0.84 | 21.08 | Upgrade
|
| Total Current Liabilities | 41.85 | 156.95 | 46.59 | 25.57 | 16.64 | 29.28 | Upgrade
|
| Long-Term Leases | 37.04 | 39 | 42.88 | 43.87 | - | - | Upgrade
|
| Long-Term Unearned Revenue | 8.06 | 16.15 | 32.32 | - | - | - | Upgrade
|
| Total Liabilities | 91.51 | 215.8 | 124.51 | 70.98 | 18.81 | 30.34 | Upgrade
|
| Common Stock | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0 | Upgrade
|
| Additional Paid-In Capital | 675.45 | 664.87 | 547.86 | 503.7 | 471.57 | 0.4 | Upgrade
|
| Retained Earnings | -404 | -438.59 | -365.89 | -230.54 | -122.04 | -48.08 | Upgrade
|
| Comprehensive Income & Other | -3.37 | -3.36 | -2.72 | -1.75 | -2.02 | -1.06 | Upgrade
|
| Total Common Equity | 268.08 | 222.94 | 179.25 | 271.41 | 347.52 | -48.73 | Upgrade
|
| Shareholders' Equity | 268.08 | 222.94 | 179.25 | 271.41 | 347.52 | 19.04 | Upgrade
|
| Total Liabilities & Equity | 359.59 | 438.73 | 303.76 | 342.39 | 366.33 | 49.38 | Upgrade
|
| Total Debt | 41.13 | 42.72 | 46.04 | 47 | - | - | Upgrade
|
| Net Cash (Debt) | 249.46 | 329.43 | 186.37 | 215.83 | 346.07 | 41.7 | Upgrade
|
| Net Cash Growth | 14.51% | 76.76% | -13.65% | -37.64% | 729.93% | 695.02% | Upgrade
|
| Net Cash Per Share | 3.02 | 4.46 | 3.63 | 4.57 | 13.84 | 27.49 | Upgrade
|
| Filing Date Shares Outstanding | 61.76 | 61.51 | 50.14 | 49.24 | 46.37 | 1.69 | Upgrade
|
| Total Common Shares Outstanding | 61.72 | 61.51 | 50.14 | 49.32 | 46.54 | 1.69 | Upgrade
|
| Working Capital | 257.61 | 220.49 | 189.62 | 250.32 | 332.03 | 14.32 | Upgrade
|
| Book Value Per Share | 4.34 | 3.62 | 3.57 | 5.50 | 7.47 | -28.91 | Upgrade
|
| Tangible Book Value | 268.08 | 222.94 | 179.25 | 271.41 | 347.52 | -48.73 | Upgrade
|
| Tangible Book Value Per Share | 4.34 | 3.62 | 3.57 | 5.50 | 7.47 | -28.91 | Upgrade
|
| Machinery | 28.59 | 27.4 | 24.23 | 18.65 | 13.06 | 5.23 | Upgrade
|
| Construction In Progress | 1.18 | 0.06 | 0.92 | 12.01 | 0.85 | - | Upgrade
|
| Leasehold Improvements | 22.71 | 22.39 | 20.89 | 2.66 | 1.12 | - | Upgrade
|
Updated Aug 7, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.